PacBio CEO's Words Haunt Patent Invalidity Arguments

By Andrew Karpan · March 25, 2024, 9:24 PM EDT

A California federal judge concluded Monday that statements made by the chief executive officer of biotech company Pacific Biosciences to investors at an earnings call undermined the company's invalidity arguments in...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Take2 Technologies Limited et al v. Pacific Biosciences of California, Inc.

Case Number

Court

California Northern

Nature of Suit

Patent

Date Filed

August 16, 2023

Recent Articles By Andrew

November 19, 2024
Judge Rejects Infosys' Bid To Seal NDAs In Trade Secrets Row
November 18, 2024
Melinta Obtains Ban On Generic Antibiotic Injections In IP Row
November 12, 2024
GOP Reps. Propose Another Bill On TRIPS Waivers
October 23, 2024
Court Denies Fees In 'Objectively Specious' Trade Secrets Suit
October 02, 2024
Avadel Tells Fed. Circ. It Should Be Free To Test Sleep Drug
September 26, 2024
2nd Circ. Denies Jury Trial In Abbott Labs Gray Market Case
September 09, 2024
Purdue Sees Another OxyContin Patent Axed
September 05, 2024
Nvidia, Microsoft Face Patent, Cartel Allegations In Texas Suit
August 09, 2024
Valeant's Legal Gripe A Total 'Nothingburger,' Justices Told
July 11, 2024
GSK Asks Judge To Rule In Teva IP Case, Citing Opioid Deals